2023 saw a cautious hope for Alzheimer's treatment but doubts remain
The US approved lecanemab to slow cognitive decline among people with early Alzheimer's, but not everyone is convinced the drug has that big of an impact – not to mention concerns over its safety and practicality
The US approved lecanemab to slow cognitive decline among people with early Alzheimer's, but not everyone is convinced the drug has that big of an impact – not to mention concerns over its safety and practicality
What's Your Reaction?
SIN
ScienceX Information Network (SIN) | ScienceX Innovations
